According to a report by CKOM on March 20, Canadian Health Minister Mark Holland has promised to crack down on nicotine pouches and claims that these products are being marketed to children.
Holland accuses the tobacco giant Imperial Tobacco of exploiting regulatory loopholes to obtain approval from Health Canada for its nicotine pouch product Zonnic, marketed as a smoking cessation aid. He argues that the product is now being used to attract a new generation of smokers. Holland has already written to all provinces outlining plans to restrict access to Zonnic, as well as its flavors and marketing.
The company responded by stating that they did not exploit any loopholes to bring Zonnic to the market, but simply applied to and received approval from Health Canada. The company expressed willingness to openly discuss the restrictions proposed by Holland, but insisted that any changes should apply to all smoking cessation products.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
